ACTA1 and renal fibrosis: Experimental treatments involving the use of an A2B adenosine receptor antagonist in diabetic rats revealed a notable decrease in glomerulosclerosis, reduced levels of collagen and α-SMA, and a significant reduction in MMT, indicating a promising approach for mitigating renal fibrosis (Cardenas et al., 2013; Torres et al., 2020).